The Predictive Value of 2D Myocardial Strain for Epirubicin-Induced Cardiotoxicity

Table 1

Patients’ characteristics and disease features.

Age, years, mean ± SD	47 ± 9
Postmenopausal women, n (%)	19 (29%)
TNM stage, n (%)	Stage I 14 (21%)
	Stage II 22 (33%)
	Stage III 19 (29%)
	Stage IV 11 (17%)
Molecular profile, n (%)	Luminal A 9 (14%)
	Luminal B 47 (71%)
	Triple negative 10 (15%)
Cancer side, n (%)	Right sided 35 (53%)
	Left sided 31 (47%)
Locoregional radiotherapy, n (%)	56 (85%)
Locoregional therapy for left-sided breast cancer, n (%)	27 (41%)